Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CCNT1 | O60563 | 7/20 | 0.35 |
| ▸ | CDK9 | P50750 | 7/20 | 0.35 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 3/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17886567 | 0.87 | MEN1 (0.42) | MEN1KMT2AGRM1NAMPTCNR1 | |
| SCHEMBL12139829 | 0.86 | BLM (0.39) | MEN1KMT2AGRM1NAMPT | |
| SCHEMBL12026525 | 0.85 | NAMPT (0.46) | MEN1KMT2ANAMPTMAPK1 | |
| SCHEMBL17886565 | 0.85 | GRM1 (0.45) | MEN1KMT2AGRM1NAMPTCNR1 | |
| SCHEMBL17886557 | 0.84 | NAMPT (0.41) | MEN1KMT2ANAMPTMAPK1KDM4E | |
| SCHEMBL17886551 | 0.83 | NAMPT (0.44) | MEN1KMT2ANAMPT | |
| SCHEMBL19226320 | 0.83 | NAMPT (0.43) | MEN1KMT2AGRM1NAMPTCNR1 | |
| SCHEMBL12026744 | 0.83 | NAMPT (0.47) | MEN1KMT2ANAMPT | |
| SCHEMBL14019815 | 0.82 | KDM4E (0.46) | MEN1KMT2ACCNT1CDK9GRM1 | |
| SCHEMBL17886560 | 0.82 | JAK1 (0.39) | MEN1KMT2AGRM1NAMPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10654828-B2 | Indole derivatives and uses thereof | NOVARTIS AG (CH) | 2020-05-19 | — | — | US | disclosed |
| US-20190055219-A1 | INDOLE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2019-02-21 | — | — | US | disclosed |
| US-9434695-B2 | Nitrogenous heterocyclic derivatives and their application in drugs | SUNSHINE LAKE PHARMA CO., LTD (CN) | 2016-09-06 | — | — | US | disclosed |
| US-20150087639-A1 | Nitrogenous Heterocyclic Derivatives And Their Application In Drugs | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150087639-A1 | Nitrogenous Heterocyclic Derivatives And Their Application In Drugs | TNNC1, TNNI3, IAPP | MEN1 61/4885KMT2A 2967/4885CCNT1 968/4885 |
| US-20190055219-A1 | INDOLE DERIVATIVES AND USES THEREOF | MYLK2, MYOF, MUSK | MEN1 2802/4885KMT2A 3973/4885CCNT1 3533/4885 |
| US-10654828-B2 | Indole derivatives and uses thereof | MYLK2, MYOF, MUSK | MEN1 2802/4885KMT2A 3973/4885CCNT1 3533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.